此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)

2026年11月6日 更新者:Liaoning Chengda Biotechnology CO., LTD

This is a prospective, open-label, randomized controlled clinical trial designed to evaluate rabies virus neutralizing antibody responses to rabies vaccination among patients infected with human immunodeficiency virus (HIV). Eligible participants will be divided into two groups according to baseline CD4+ T cell count before randomization. Within each group, participants will be randomly assigned to one of two different rabies vaccination regimens for simulated post-exposure prophylaxis. Blood samples will be collected before vaccination and at scheduled time points after vaccination. Rabies virus neutralizing antibody titers will be tested to assess the seroconversion rate and geometric mean concentration (GMC). Adverse events after vaccination will also be recorded.

研究概览

详细说明

This prospective, open-label, randomized controlled clinical trial will enroll HIV-infected patients aged 18-60 years who are receiving antiretroviral therapy (ART). A total of 160 eligible participants will be divided into two groups based on baseline CD4+ T cell count (<350 cells/mm³ vs. ≥350 cells/mm³) before randomization, with 80 subjects in each group. Within each group, participants will be randomized in a 1:1 ratio to receive freeze-dried human rabies vaccine (Vero cell) under the Zagreb regimen or the Essen regimen.

Serum samples will be collected at scheduled time points according to different vaccination regimens. For participants assigned to the Zagreb regimen, blood samples will be obtained on Day 0, Day 14, Day 35, and three months after completion of the full vaccination course. For participants assigned to the Essen regimen, blood samples will be collected on Day 0, Day 14, Day 28, Day 42, and three months after completion of the full vaccination course. Rabies virus neutralizing antibody titers will be measured for all collected serum samples, and seroconversion rate and GMC will be calculated to assess immune responses at each predefined time point.

Participants with rabies virus neutralizing antibody titers lower than 0.5 IU/mL at 14 days after completion of the full vaccination course will receive booster vaccination on Day 0 and Day 3. Blood samples will be collected 14 days after booster administration to measure rabies virus neutralizing antibody titers. Seroconversion rate and GMC will be calculated to evaluate immune responses after booster vaccination.

Adverse events will be monitored throughout the study. All immediate adverse events occurring within 30 minutes after each dose will be recorded. Solicited adverse events will be monitored for 7 days after each dose. Unsolicited adverse events will be monitored from day 8 to day 14 following each dose.

研究类型

介入性

注册 (估计的)

160

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangxi
      • Nanning、Guangxi、中国、530028
        • 招聘中
        • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
        • 接触:
        • 首席研究员:
          • Jingxia Luo
      • Nanning、Guangxi、中国、530012
        • 招聘中
        • The Fourth People's Hospital of Nanning City
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • HIV-infected participants aged 18 to 60 years, able to provide valid identification.
  • Normal liver and renal function confirmed by laboratory testing within 7 days prior to screening or on the day of screening.
  • Receiving antiretroviral therapy (ART) for at least 6 months with a stable CD4+ T cell count ≥350 cells/mm³; or receiving ART for at least 6 months with a CD4+ T cell count <350 cells/mm³ and previously treated, well-controlled opportunistic infections (no clinical signs of active opportunistic infection, normal routine blood tests, and normal liver and renal test results).
  • No active opportunistic infection or tumor, no history of drug allergy, and no other severe acute or chronic illnesses.
  • Willing to participate in the study voluntarily and provide written informed consent.
  • Participants are able to attend all scheduled visits as required by the protocol, with no plans for long term absence or relocation away from the study site.
  • Axillary temperature ≤37.2℃ at screening.

Exclusion Criteria:

  • History of rabies vaccination.
  • History of receiving any blood, blood products or immunoglobulin within 3 months prior to the first vaccine dose, or plans to use these products within 1 month after the last vaccine dose.
  • Receipt of immunosuppressive therapy within 3 months prior to enrollment, including continuous administration of systemic glucocorticoids (for 14 days or longer at a dose of ≥20 mg per day).
  • Participating in another clinical trial (vaccine or drug) or planning to participate in another clinical trial during the course of this trial.
  • Confirmed pregnancy (positive urine pregnancy test at enrollment), or women of childbearing potential planning to become pregnant within 2 months.
  • History of allergy to any component of the study vaccine, including excipients and antibiotics.
  • Presence of any acute disease, or chronic disease in active phase.
  • History of serious adverse events following administration of other vaccines.
  • Any condition that may interfere with study outcomes or study procedures, as assessed by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Zagreb regimen (CD4+ T cell count ≥350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7, and 1 dose on day 21, for a total of 4 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

其他名称:
  • 速比达
实验性的:Essen regimen (CD4+ T cell count ≥350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

其他名称:
  • 速比达
实验性的:Zagreb regimen (CD4+ T cell count <350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count <350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7 and 1 dose on day 21, for a total of 4 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

其他名称:
  • 速比达
实验性的:Essen regimen (CD4+ T cell count <350 cells/mm³)

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count <350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses.

0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

其他名称:
  • 速比达

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination course
大体时间:14 days after completion of the full vaccination course

Seroconversion rate and GMC of rabies virus neutralizing antibodies among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by the rapid fluorescent focus inhibition test (RFFIT).

14 days after completion of the full vaccination course
Incidence of adverse events after vaccination
大体时间:30 minutes, 0-7 days, and 8-14 days after each vaccine dose

Incidence of immediate local and systemic adverse events recorded within 30 minutes after each vaccination; incidence of solicited local and systemic adverse events collected 0-7 days after each dose; incidence of unsolicited adverse events collected 8-14 days after each dose. Adverse events are defined as any untoward medical occurrence in a participant administered vaccine, not necessarily having a causal relationship with vaccination.

30 minutes, 0-7 days, and 8-14 days after each vaccine dose

次要结果测量

结果测量
措施说明
大体时间
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 14 days after the first dose of vaccination
大体时间:14 days after the first dose of vaccination

Seroconversion rate and GMC of rabies virus neutralizing antibodies at 14 days after the first dose vaccination among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT.

14 days after the first dose of vaccination
Seroconversion rate and GMC of rabies virus neutralizing antibodies at 90 days after completion of the full vaccination course
大体时间:90 days after completion of the full vaccination course

Seroconversion rate and GMC of rabies virus neutralizing antibodies at 90 days after completion of the full vaccination course among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT.

90 days after completion of the full vaccination course
Seroconversion rate and GMC of rabies virus neutralizing antibodies after booster vaccination
大体时间:14 days after booster vaccination

Seroconversion rate and GMC of rabies virus neutralizing antibodies 14 days after booster vaccination, in participants who remain seronegative (titer <0.5 IU/mL) at 14 days after completion of the full vaccination course. Booster vaccination consists of 2 doses administered on day 0 and day 3 of the booster phase. Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by RFFIT.

14 days after booster vaccination
Seroconversion rate and GMC of rabies virus neutralizing antibodies at Day 28 within the Essen regimen group
大体时间:Day 28 within the Essen vaccination regimen

Seroconversion rate and GMC of rabies virus neutralizing antibodies at Day 28 among HIV-infected participants who are seronegative at baseline (Day 0) and assigned to the Essen five dose regimen. Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralising antibodies will be assessed by RFFIT.

Day 28 within the Essen vaccination regimen

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月8日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2028年6月30日

研究注册日期

首次提交

2026年11月6日

首先提交符合 QC 标准的

2026年11月6日

首次发布 (实际的)

2026年11月12日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月6日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅